Results 31 to 40 of about 29,323 (206)

Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling

Journal of Lipid Research, 2009
The sphingolipid metabolite sphingosine-1-phosphate (S1P) and the kinases that produce it have emerged as critical regulators of numerous fundamental biological processes important for health and disease.
Michael Maceyka, Sheldon Milstien, Sarah Spiegel   +2 more
doaj   +1 more source

Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation [PDF]

Advances in Biological Regulation, 2016
Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to intracellular target proteins, such as HDAC1/2, to induce cell responses.
Pyne, Nigel J., McNaughton, Melissa, Boomkamp, Stephanie, MacRitchie, Neil, Evangelisti, Cecilia, Martelli, Alberto M., Jiang, Hui-Rong, Ubhi, Satvir Kaur, Pyne, Susan   +8 more
openaire   +5 more sources

Sphingosine-1–Phosphate, FTY720, and Sphingosine-1–Phosphate Receptors in the Pathobiology of Acute Lung Injury [PDF]

American Journal of Respiratory Cell and Molecular Biology, 2013
Abstract Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality.
Viswanathan, Natarajan, Steven M, Dudek, Jeffrey R, Jacobson, Liliana, Moreno-Vinasco, Long Shuang, Huang, Taimur, Abassi, Biji, Mathew, Yutong, Zhao, Lichun, Wang, Robert, Bittman, Ralph, Weichselbaum, Evgeny, Berdyshev, Joe G N, Garcia   +12 more
openaire   +2 more sources

Unraveling A4GALT Mechanism and Its Modulation With Adamantyl‐Galactosylceramide Analogues: Advancing Fabry Disease Therapeutic Strategies

Angewandte Chemie, EarlyView.
A 310‐helix‐mediated conformational switch promotes a front‐face SNi‐like catalysis by human A4GALT. Mechanism‐guided design identifies AdaGalCer as a selective modulator of globotriaosylceramide (Gb3) biosynthesis, opening a clear route toward new Fabry disease therapeutics.
Nicky de Koster, Òscar Vidal‐Gironès, Rowan de Graaf, Ken Kok, Lindsey T. Lelieveld, Jackelien Hoogervorst, Maria J. Ferraz, José Pablo Rivas‐Fernández, Rob F. Lammers, Herman S. Overkleeft, Johannes M. F. G. Aerts, Rolf G. Boot, Carme Rovira, Marta Artola   +13 more
wiley   +2 more sources

Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts

Frontiers in Physiology, 2018
Platelets affect myocardial damage from ischemia/reperfusion. Redox-dependent sphingosine-1-phosphate production and release are altered in diabetic platelets. Sphingosine-1-phosphate is a double-edged sword for ischemia/reperfusion injury. Therefore, we
Isabella Russo, Saveria Femminò, Saveria Femminò, Cristina Barale, Francesca Tullio, Francesca Tullio, Stefano Geuna, Franco Cavalot, Franco Cavalot, Pasquale Pagliaro, Pasquale Pagliaro, Claudia Penna, Claudia Penna   +12 more
doaj   +1 more source

Insulin protects apoptotic cardiomyocytes from hypoxia/reoxygenation injury through the sphingosine kinase/sphingosine 1-phosphate axis.

PLoS ONE, 2013
ObjectiveExperimental and clinical studies have shown that administration of insulin during reperfusion is cardioprotective, but the mechanisms underlying this effect are still unknown.
Huan Yu, Xiangxin Che, Xiaoyuan Xu, Meirong Zheng, Yong Zhao, Wei He, Jingmou Yu, Jianjun Xiong, Weidong Li   +8 more
doaj   +1 more source

Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2*

Journal of Lipid Research, 2009
Sphingosine 1-phosphate (S1P), a bioactive lipid mediator, stimulates proliferation and contractility in hepatic stellate cells, the principal matrix-producing cells in the liver, and inhibits proliferation via S1P receptor 2 (S1P2) in hepatocytes in ...
Hitoshi Ikeda, Naoko Watanabe, Isao Ishii, Tatsuo Shimosawa, Yukio Kume, Tomoaki Tomiya, Yukiko Inoue, Takako Nishikawa, Natsuko Ohtomo, Yasushi Tanoue, Satoko Iitsuka, Ryoto Fujita, Masao Omata, Jerold Chun, Yutaka Yatomi   +14 more
doaj   +1 more source

S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

Acta Pharmaceutica Sinica B, 2023
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2–3 years and there is no effective intervention to treat IPF other than ...
Mengyao Hao, Rong Fu, Jun Tai, Zhenhuan Tian, Xia Yuan, Yang Chen, Mingjin Wang, Huimin Jiang, Ming Ji, Fangfang Lai, Nina Xue, Liping Bai, Yizhun Zhu, Xiaoxi Lv, Xiaoguang Chen, Jing Jin   +15 more
doaj   +1 more source

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

FEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain, Elise Buret, Le Hoang Thanh Nguyen, Marion Cocheteux, Nicolas Touya, Mélanie Dhayer, Romain Dubois, Frank Lafont, Sebastien Janel, Patrice Maboudou, Steve Lancel, Philippe Marchetti   +11 more
wiley   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source